US threatens Swiss pharma with trade probe a week after Germany

The US could open a Section 301 trade investigation into Switzerland's pharmaceutical industry over pricing practices, Interpharma said Friday, widening a crackdown that began against Germany last week.

"The US Trade Representative is examining Swiss pharmaceutical pricing mechanisms with a view to potential trade action," the head of Interpharma, Switzerland's pharmaceutical industry body, said in a statement. "This follows a similar review initiated against Germany."

The probe targets Switzerland's system of mandatory healthcare price controls, which US officials argue disadvantages American drug makers. Swiss pharmaceutical exports to the US represent a significant portion of the country's trade surplus, with companies including Roche Holding AG, Novartis AG and Lonza Group AG generating substantial revenue from the American market. A group of Republican US lawmakers recently pressed for Section 301 investigations into countries with restrictive pharmaceutical pricing policies, according to reports.

A Section 301 investigation could lead to tariffs or other trade restrictions on Swiss pharmaceutical imports, potentially disrupting supply chains for critical medicines. The probe would mark the second such action against a European pharmaceutical pricing regime in as many weeks, following the US investigation into Germany's healthcare spending reforms. The previous Section 301 investigation into Chinese intellectual property practices in 2018 led to tariffs on hundreds of billions of dollars in Chinese goods, setting a precedent for the potential scale of trade action.

Switzerland's Pricing Review Draws Scrutiny

The Swiss government is currently reviewing its mandatory healthcare pricing system, a process that has drawn attention from US trade officials. Switzerland's pharmaceutical sector accounts for about a third of the country's total exports, making it the most important industry for the Swiss economy.

The US investigation into Germany was triggered by Berlin's plans to cut pharmaceutical spending through reference pricing and mandatory rebates. Washington argued those measures unfairly limit returns for US drug makers. Switzerland's similar review of healthcare pricing puts it in the crosshairs of US trade enforcement. The approach has faced pushback from pharmaceutical firms, which argue that pricing controls are a sovereign health policy matter, not a trade issue.

For Swiss pharma companies, the stakes are high. Roche, the world's largest cancer drug maker, generates about half its sales in the US. Novartis, which operates a significant US business through its Sandoz generics unit and innovative medicines division, similarly depends on the American market. Lonza, a contract drug manufacturer, counts major US pharmaceutical companies among its clients. Any tariffs or trade restrictions would directly affect their profitability and could force adjustments to their US operations.

The broader implications extend beyond Switzerland. The US actions against Germany and Switzerland signal a more aggressive approach to pharmaceutical pricing disputes, potentially targeting other countries with similar healthcare cost-containment policies. European nations including France, Italy and Spain all operate some form of drug price regulation that Washington could challenge under Section 301.

The US has not specified a timeline for the investigation or potential retaliatory measures. The Section 301 process typically involves a period of public comment and consultation before any trade action is taken. If the investigation proceeds, it could take months before any tariffs or restrictions are imposed, giving both sides time to negotiate.

This article is for informational purposes only and does not constitute investment advice.